Patents by Inventor Steven Martin Ogbourne
Steven Martin Ogbourne has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10143638Abstract: The present invention relates generally to the cosmetic treatment of aged skin. More specifically, the invention relates to the use of ingenol compounds, particularly ingenol angelates, in treating photo-aged and/or chronologically-aged skin.Type: GrantFiled: February 12, 2010Date of Patent: December 4, 2018Assignee: LEO Laboratories LimitedInventors: Steven Martin Ogbourne, David Thomas, Ryan Moseley, James Harrison Aylward
-
Patent number: 9895334Abstract: The present invention relates generally to the treatment of cutaneous lesions containing cells infected by a virus, as well as compositions for the treatment of such lesions. More specifically, the invention relates to the use of ingenol compounds, particularly ingenol angelates, in treating lesions caused by infection with a papilloma virus, such as a mammalian papilloma virus, in particular a Human Papilloma Virus.Type: GrantFiled: April 30, 2008Date of Patent: February 20, 2018Assignee: LEO Laboratories LimitedInventors: Steven Martin Ogbourne, Andreas Suhrbier, James Harrison Aylward
-
Publication number: 20170119719Abstract: The present invention relates to novel crystalline forms of ingenol ingenol-3-angelate and methods of preparation and use thereof. More specifically, the invention relates to a novel crystalline form and purified forms of the compound of Formula 1 (ingenol-3-mebutate; ingenol-3-angelate; isoform ‘b’; PEP005), which is characterized by, for example, attenuated total reflectance Fourier transform infrared (FTIR-ATR) spectroscopy, single crystal X-Ray crystallography (XRC), X-ray powder diffraction, and, Differential Scanning calorimetry (DSC), and methods of preparation and use thereof.Type: ApplicationFiled: November 14, 2016Publication date: May 4, 2017Inventor: Steven Martin Ogbourne
-
Publication number: 20160317486Abstract: The present invention relates generally to methods and compositions for promoting wound healing in a subject. In particular, the invention relates to the use of ingenol compounds, particularly ingenol angelates, in wound healing and compositions thereof which contain such compounds.Type: ApplicationFiled: April 18, 2016Publication date: November 3, 2016Inventors: Steven Martin Ogbourne, David Thomas, Ryan Moseley
-
Patent number: 9440906Abstract: The present invention relates to a novel crystalline form of ingenol mebutate, methods of preparation thereof, and to its use. More specifically, the invention relates to the conversion of amorphous ingenol mebutate (ingenol-3-angelate, PEP005) to a crystalline form, which was characterized by single crystal X-Ray crystallography (XRC), attenuated total reflectance Fourier transform infrared (FTIR-ATR) spectroscopy and Differential Scanning calorimetry (DSC).Type: GrantFiled: February 17, 2014Date of Patent: September 13, 2016Assignee: LEO Laboratories LimitedInventor: Steven Martin Ogbourne
-
Publication number: 20150025265Abstract: The present invention relates to a novel crystalline form of ingenol mebutate, methods of preparation thereof, and to its use. More specifically, the invention relates to the conversion of amorphous ingenol mebutate (ingenol-3-angelate, PEP005) to a crystalline form, which was characterized by single crystal X-Ray crystallography (XRC), attenuated total reflectance Fourier transform infrared (FTIR-ATR) spectroscopy and Differential Scanning calorimetry (DSC).Type: ApplicationFiled: February 17, 2014Publication date: January 22, 2015Applicant: LEO LABORATORIES LIMITEDInventor: Steven Martin Ogbourne
-
Publication number: 20140242012Abstract: The present invention is directed to the prophylatic field treatment of photodamaged skin with topical ingenol mebutate. More specifically, the present invention concerns field-directed treatment of UV-damaged skin with topical ingenol mebutate for reducing the number of skin lesions that emerge from the UV-damaged skin over time. In addition, the present invention concerns field-directed treatment for removing photodamaged skin, mutated keratinocytes, cutaneous immunosuppressive environments and/or p53+ patches caused by UV with topical ingenol mebutate. By way of example, the present invention is directed to treating photodamaged skin with topical ingenol mebutate at about 0.05% concentration. The present invention is also concerned with the treatment of SCC tumors with topical ingenol mebutate for reducing the number of SCC tumors. By example, the present invention is directed to treating and curing SCC xenografts with topical ingenol mebutate at about 0.25% concentration.Type: ApplicationFiled: December 23, 2013Publication date: August 28, 2014Inventors: Sarah-Jane Cozzi, Andreas Suhrbier, Steven Martin Ogbourne
-
Patent number: 8653133Abstract: The present invention relates to a novel crystalline form of ingenol mebutate, methods of preparation thereof, and to its use. More specifically, the invention relates to the conversion of amorphous ingenol mebutate (ingenol-3-angelate, PEP005) to a crystalline form, which was characterized by single crystal X-Ray crystallography (XRC), attenuated total reflectance Fourier transform infrared (FTIR-ATR) spectroscopy and Differential Scanning calorimetry (DSC).Type: GrantFiled: April 18, 2011Date of Patent: February 18, 2014Assignee: LEO Laboratories LimitedInventor: Steven Martin Ogbourne
-
Publication number: 20120276045Abstract: The present invention relates generally to the field of cancer including tumor therapy. More particularly, the present invention relates to the treatment of solid cancers, including solid tumors, and the prevention or reduction of cancer metastasis, by chemoablation of cancer cells by an agent which also stimulates the generation of cancer-specific T-cells, a process referred to herein as immunostimulatory chemoablation. The present invention further contemplates combination therapy comprising immunostimulatory chemoablation and one or more other therapeutic regimens, which enhance, co-operate and/or synergize with the cancer-specific T-cells induced by the chemoablation. The present invention also relates to pharmaceutical compositions for use in treating cancers.Type: ApplicationFiled: January 30, 2012Publication date: November 1, 2012Applicant: Leo Laboratories LimitedInventors: Steven Martin Ogbourne, Andreas Suhrbier
-
Publication number: 20120041064Abstract: The present invention relates generally to the cosmetic treatment of aged skin. More specifically, the invention relates to the use of ingenol compounds, particularly ingenol angelates, in treating photo-aged and/or chronologically-aged skin.Type: ApplicationFiled: February 12, 2010Publication date: February 16, 2012Applicant: PEPLIN RESEARCH PTY LTDInventors: Steven Martin Ogbourne, David Thomas, Ryan Moseley, James Harrison Aylward
-
Patent number: 8106092Abstract: The present invention relates generally to the field of cancer including tumor therapy. More particularly, the present invention relates to the treatment of solid cancers, including solid tumors, and the prevention or reduction of cancer metastasis, by chemoablation of cancer cells by an agent which also stimulates the generation of cancer-specific T-cells, a process referred to herein as immunostimulatory chemoablation. The present invention further contemplates combination therapy comprising immunostimulatory chemoablation and one or more other therapeutic regimens, which enhance, co-operate and/or synergize with the cancer-specific T-cells induced by the chemoablation. The present invention also relates to pharmaceutical compositions for use in treating cancers.Type: GrantFiled: December 2, 2005Date of Patent: January 31, 2012Assignee: LEO Laboratories LimitedInventors: Steven Martin Ogbourne, Andreas Suhrbier
-
Publication number: 20110257262Abstract: The present invention relates to a novel crystalline form of ingenol mebutate, methods of preparation thereof, and to its use. More specifically, the invention relates to the conversion of amorphous ingenol mebutate (ingenol-3-angelate, PEP005) to a crystalline form, which was characterized by single crystal X-Ray crystallography (XRC), attenuated total reflectance Fourier transform infrared (FTIR-ATR) spectroscopy and Differential Scanning calorimetry (DSC).Type: ApplicationFiled: April 18, 2011Publication date: October 20, 2011Applicant: LEO PHARMA A/SInventor: Steven Martin OGBOURNE
-
Publication number: 20100204318Abstract: The present invention relates generally to the treatment of cutaneous lesions containing cells infected by a virus, as well as compositions for the treatment of such lesions. More specifically, the invention relates to the use of ingenol compounds, particularly ingenol angelates, in treating lesions caused by infection with a papilloma virus, such as a mammalian papilloma virus, in particular a Human Papilloma Virus.Type: ApplicationFiled: April 30, 2008Publication date: August 12, 2010Applicant: PEPLIN RESEARCH PTY LTDInventors: Steven Martin Ogbourne, Andreas Suhrbier, James Harrison Aylward
-
Publication number: 20090215884Abstract: The present invention relates generally to methods and compositions for promoting wound healing in a subject. In particular, the invention relates to the use of ingenol compounds, particularly ingenol angelates, in wound healing and compositions therefor which contain such compounds.Type: ApplicationFiled: November 24, 2006Publication date: August 27, 2009Applicant: PEPLIN RESEARCH PTY LTD.Inventors: Steven Martin Ogbourne, David Thomas, Ryan Moseley
-
Publication number: 20080187513Abstract: The present invention relates generally to the field of cancer including tumor therapy. More particularly, the present invention relates to the treatment of solid cancers, including solid tumors, and the prevention or reduction of cancer metastasis, by chemoablation of cancer cells by an agent which also stimulates the generation of cancer-specific T-cells, a process referred to herein as immunostimulatory chemoablation. The present invention further contemplates combination therapy comprising immunostimulatory chemoablation and one or more other therapeutic regimens, which enhance, co-operate and/or synergize with the cancer-specific T-cells induced by the chemoablation. The present invention also relates to pharmaceutical compositions for use in treating cancers.Type: ApplicationFiled: December 2, 2005Publication date: August 7, 2008Applicant: Peplin Research Pty Ltd.Inventors: Steven Martin Ogbourne, Andreas Suhrbier